{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:00:15Z","timestamp":1785243615091,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Swiss National Research Foundation","award":["320030-120686"],"award-info":[{"award-number":["320030-120686"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40262-019-00821-w","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T09:09:16Z","timestamp":1569402556000},"page":"371-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic\/Pharmacodynamic Analyses"],"prefix":"10.1007","volume":"59","author":[{"given":"Ana\u00efs","family":"Glatard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Delacr\u00e9taz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dubath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermine","family":"Laaboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-0230","authenticated-orcid":false,"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"issue":"12","key":"821_CR1","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","volume":"57","author":"MC Mauri","year":"2018","unstructured":"Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493\u2013528.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"821_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jpsychires.2005.10.003","volume":"41","author":"MJ Muller","year":"2007","unstructured":"Muller MJ, Regenbogen B, Hartter S, Eich FX, Hiemke C. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res. 2007;41(8):673\u20139.","journal-title":"J Psychiatr Res"},{"key":"821_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"issue":"1\u201302","key":"821_CR4","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"821_CR5","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421\u201353.","journal-title":"CNS Drugs"},{"issue":"12","key":"821_CR6","doi-asserted-by":"publisher","first-page":"e1557","DOI":"10.4088\/JCP.15m10538","volume":"77","author":"Y Iwata","year":"2016","unstructured":"Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, et al. Threshold of dopamine D2\/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia. J Clin Psychiatry. 2016;77(12):e1557\u201363.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"821_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","volume":"40","author":"I Besnard","year":"2014","unstructured":"Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance [in French]. Encephale. 2014;40(1):86\u201394.","journal-title":"Encephale"},{"key":"821_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/DHPS.S6226","volume":"2","author":"MF Juruena","year":"2010","unstructured":"Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205\u201311.","journal-title":"Drug Healthc Patient Saf"},{"issue":"2","key":"821_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","volume":"74","author":"RI Holt","year":"2011","unstructured":"Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.psychres.2019.02.017","volume":"274","author":"SW During","year":"2019","unstructured":"During SW, Nielsen MO, Bak N, Glenthoj BY, Ebdrup BH. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2\/3 receptor blockade: an exploratory study. Psychiatry Res. 2019;274:58\u201365.","journal-title":"Psychiatry Res"},{"issue":"18","key":"821_CR11","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s00213-016-4379-6","volume":"233","author":"S Reeves","year":"2016","unstructured":"Reeves S, Bertrand J, D\u2019Antonio F, McLachlan E, Nair A, Brownings S, et al. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer\u2019s disease. Psychopharmacology (Berl). 2016;233(18):3371\u201381.","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"821_CR12","doi-asserted-by":"publisher","first-page":"e844","DOI":"10.4088\/JCP.16m11216","volume":"78","author":"S Reeves","year":"2017","unstructured":"Reeves S, Bertrand J, McLachlan E, D\u2019Antonio F, Brownings S, Nair A, et al. A population approach to guide amisulpride dose adjustments in older patients with Alzheimer\u2019s disease. J Clin Psychiatry. 2017;78(7):e844\u201351.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"821_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00213-003-1721-6","volume":"173","author":"S Leucht","year":"2004","unstructured":"Leucht S, Wagenpfeil S, Hamann J, Kissling W. Amisulpride is an \u201catypical\u201d antipsychotic associated with low weight gain. Psychopharmacology (Berl). 2004;173(1\u20132):112\u20135.","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"821_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","volume":"56","author":"A Ivanyuk","year":"2017","unstructured":"Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"821_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"821_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"821_CR17","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","volume":"17","author":"MP Pai","year":"2010","unstructured":"Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17:e53\u201362.","journal-title":"Adv Chronic Kidney Dis"},{"key":"821_CR18","volume-title":"NONMEM User\u2019s Guides (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User\u2019s Guides (1989\u20132009). Ellicott City: Icon Development Solutions; 2009."},{"key":"821_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"821_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"key":"821_CR21","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2018","unstructured":"Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. New York: Wiley Blackwell; 2018.","edition":"13"},{"issue":"2 Suppl","key":"821_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0269881107087373","volume":"22","author":"L Citrome","year":"2008","unstructured":"Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol. 2008;22(2 Suppl):90\u20137.","journal-title":"J Psychopharmacol"},{"key":"821_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hup.320","volume":"17","author":"P Rosenzweig","year":"2002","unstructured":"Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17:1\u201313.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"821_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.euroneuro.2003.09.001","volume":"14","author":"N Bergemann","year":"2004","unstructured":"Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14(3):245\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"821_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1208\/s12248-014-9649-9","volume":"16","author":"JN Dos Santos Pereira","year":"2014","unstructured":"Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA, et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J. 2014;16:1247\u201358.","journal-title":"AAPS J"},{"key":"821_CR26","unstructured":"Solian\u00ae comprim\u00e9s. \nhttp:\/\/www.swissmedicinfo.ch\/\n\n. Accessed 14 Jan 2019."},{"issue":"9","key":"821_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jamapsychiatry.2015.0891","volume":"72","author":"A Graff-Guerrero","year":"2015","unstructured":"Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, et al. Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2\/3 receptor occupancy study. JAMA Psychiatry. 2015;72(9):927\u201334.","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"821_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14656566.2017.1288722","volume":"18","author":"B Lange","year":"2017","unstructured":"Lange B, Mueller JK, Leweke FM, Bumb JM. How gender affects the pharmacotherapeutic approach to treating psychosis\u2014a systematic review. Expert Opin Pharmacother. 2017;18(4):351\u201362.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"821_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1600-0447.2009.01429.x","volume":"120","author":"A Sparshatt","year":"2009","unstructured":"Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride \u2013 dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand. 2009;120(6):416\u201328.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"821_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","volume":"33","author":"IM Lako","year":"2013","unstructured":"Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33(5):675\u201381.","journal-title":"J Clin Psychopharmacol"},{"key":"821_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","volume":"45","author":"T Tsuboi","year":"2013","unstructured":"Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, et al. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:178\u201382.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"821_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","volume":"58","author":"JX Chen","year":"2015","unstructured":"Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130\u201340.","journal-title":"Psychoneuroendocrinology"},{"issue":"22","key":"821_CR33","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","volume":"234","author":"J Grigg","year":"2017","unstructured":"Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017;234(22):3279\u201397.","journal-title":"Psychopharmacology (Berl)"},{"key":"821_CR34","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2147\/NDT.S135666","volume":"13","author":"Y Huang","year":"2017","unstructured":"Huang Y, Ma H, Wang Y, Peng M, Zhu G. Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia. Neuropsychiatr Dis Treat. 2017;13:1395\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"20","key":"821_CR35","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314.","journal-title":"Drugs"},{"issue":"1","key":"821_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1210\/jcem-67-1-116","volume":"67","author":"JD Veldhuis","year":"1988","unstructured":"Veldhuis JD, Johnson ML. Operating characteristics of the hypothalamo-pituitary\u2013gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 1988;67(1):116\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"821_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/159402","author":"AL Rosenbloom","year":"2010","unstructured":"Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in children and adolescents. Int J Pediatr Endocrinol. 2010. \nhttps:\/\/doi.org\/10.1155\/2010\/159402\n\n.","journal-title":"Int J Pediatr Endocrinol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00821-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T01:22:15Z","timestamp":1600910535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00821-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00821-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"25 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work has been funded in part by the Swiss National Research Foundation (CE and PC: 320030-120686, 324730-144064, and 320030-173211). The funding sources had no role in the writing of the manuscript or in the decision to submit the manuscript for publication. CE received honoraria for conferences or teaching continuing medical education courses from Astra Zeneca, Forum f\u00fcr Medizinische Fortbildung, Janssen-Cilag, Lundbeck, Mepha, Otsuka, Sandoz, Servier, Vifor-Pharma and Zeller over the past 3 years, and for writing a review article for the journal \u2018Dialogues in Clinical Neurosciences\u2019 (Servier).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ana\u00efs Glatard, Monia Guidi, Aur\u00e9lie Delacr\u00e9taz, C\u00e9line Dubath, Claire Grosu, Nermine Laaboub, Armin von Gunten, Philippe Conus, Chantal Csajka and Chin B. Eap declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}